(Press-News.org) COLUMBUS, Ohio - Some RNA molecules spend time in a restful state akin to hibernation rather than automatically carrying out their established job of delivering protein-building instructions in cells, new research suggests.
And instead of being a fluke or a mistake, the research suggests that this restful period appears to be a programmed step for RNA produced by certain types of genes, including some that control cell division and decide where proteins will work in a cell to sustain the cell's life.
This could mean that protein production in cells is not as clear-cut as biology textbooks suggest, scientists say.
"This could mean there are more variations to the proteins in our bodies than we realize; it means that RNAs can be stored and reactivated and we don't know what biological process that affects - it could influence embryonic development, or neurological activity, or even cancer," said Daniel Schoenberg, professor of molecular and cellular biochemistry at Ohio State University and lead author of the study.
Schoenberg and colleagues discovered this phenomenon by tracing the origins of a cap-like structure on messenger RNA (mRNA) that is known to coordinate most of this RNA molecule's short life. Messenger RNA is manufactured in a cell's nucleus and each mRNA contains the instructions needed to produce a specific protein that a cell needs to live.
Until now, scientists have believed that once an mRNA is no longer needed to make protein, the cap comes off and the molecule is degraded, its job complete. But Schoenberg's lab discovered in 2009 that some mRNAs that were thought to be degraded were instead still present in the cell, but they were missing part of their sequence and had caps placed back on the newly formed ends. Because these mRNAs were in the cytoplasm, the changes had to happen there rather than inside the nucleus.
In this new study, the researchers were looking for further evidence of these apparent rogue mRNAs, but instead they found that a completely unexpected biological process occurs before some proteins are even a glimmer in a gene's eye: The uncapping and recapping of mRNAs outside the nucleus results from a cap recycling operation in the cell cytoplasm. This process appeared to enable certain RNAs to pause, without being degraded, before launching protein production.
"What this discovery tells us is a complete fundamental reworking of the relationship between a gene, messenger RNA and a protein. It's more complicated than we realize," Schoenberg said.
The research is published online in the open-access journal Cell Reports.
That fragments of mRNA could exist at all in the cell's main body was first reported by other scientists in 1992. Years later, Schoenberg asked a postdoctoral researcher in his lab to revisit these unexpected RNA fragments and confirm they exist. The postdoc's experiments showed that these mRNA, thought to be the dregs left over from their degradation, had caps on them - suggesting they still had the potential to function in protein production. Schoenberg, also director of Ohio State's Center for RNA Biology, has been investigating this cytoplasmic capping operation ever since.
In 2009, he and colleagues reported the discovery of two enzymes in the cell's main body that would enable mRNA capping to occur completely outside the nucleus and in the cytoplasm instead.
In the current studies, Schoenberg sought to determine the physiological significance of this capping operation. The researchers engineered a way to block cytoplasmic capping in cells in the lab and then looked at changes in more than 55,000 RNAs.
This interference with cytoplasmic capping revealed that two different types of pathways could exist in the cells - some mRNAs remained stable without their caps, while others without caps were rapidly destroyed. This finding indicated that mRNAs can lose their caps in the cytoplasm and at some point get recapped. With further experimentation, the researchers determined that only some mRNAs lost their caps in the cell body.
"It's not all of any particular message that's uncapped, just a portion of a message," Schoenberg said. "We wanted to show that we have uncapped RNAs in the cell and they are not degraded. It means they're stored that way."
This finding offered hints that there is a higher order to this phenomenon, and that some mRNAs purposefully rest in an uncapped state without being degraded by enzymes within the cell whose job is to remove them. It also suggested that as the capping circumstances change inside the cell body, signals from genes might undergo change that allows for two or more proteins, one being shorter than the other, to be made from the same mRNA.
"We have always thought that one gene would give an mRNA for one kind of protein. But what we have found makes us wonder if multiple proteins could be made from each of the messenger RNAs that undergo decapping and recapping in the cytoplasm," Schoenberg said.
The researchers used bioinformatics technology to determine which genes were manufacturing mRNAs that could exist in this uncapped and recapped state in the cytoplasm. These genes included those that control some of the most basic elements of cell survival: They determine the location of proteins and RNAs within the cell and, perhaps most significantly, the mitotic cell cycle - part of the process of cell division.
"It wasn't random. It was very specific," Schoenberg said. "There are specific families of mRNAs that are regulated in this way, and that has ramifications for how proteins are expressed and regulated."
As an example, he cited how neurons communicate messages across vast distances to other nerve cells. It is known that mRNAs are deliberately kept in a silent state while they travel from, for example, the spinal cord to the fingertip, where they are then activated to make new proteins.
"What would the condition be of the mRNA to keep it silent? The possibility is it doesn't have a cap on it, and if it doesn't, it can't be translated. Maybe cytoplasmic capping in neurons is a function that allows that message to be translated at just the right time," Schoenberg said.
Or, in the case of cancer: "What if one of the things that happens is you are making shortened proteins instead of full-length proteins and the regulatory part of the protein is missing in the shortened protein? If that's true, can you interfere with this process and interfere with malignancy as a result?"
For now, these scientists can only speculate about what this unexpected biological process really means. Schoenberg's lab plans to investigate the phenomenon more thoroughly in a line of breast cancer cells.
###
This work is supported by the National Institute of General Medical Sciences.
Co-authors include Chandrama Mukherjee, Deepak Patil, Brian Kennedy and Baskar Bakthavachalu of the Department of Molecular and Cellular Biochemistry; and Ralf Bundschuh of the departments of Physics and Biochemistry, all at Ohio State. All also are members of the Center for RNA Biology.
Contact: Daniel Schoenberg, (614) 688-3012; Schoenberg.3@osu.edu
Written by Emily Caldwell, (614) 292-8310; Caldwell.151@osu.edu
To cap or not to cap: Scientists find new RNA phenomenon that challenges dogma
2012-08-27
ELSE PRESS RELEASES FROM THIS DATE:
Tests show that adhesive could improve safety of LASIK eye surgery
2012-08-27
MANHATTAN, Kan. -- Kansas State University researchers have developed a glue mixture that may reduce risks after laser vision correction surgery.
Stacy Littlechild, a recent bachelor's degree graduate in biology originally from Wakeeney, is the lead author of two studies that describe a new protocol involving fibrinogen, riboflavin and ultraviolet light that could improve the safety of the corrective surgery.
One study that demonstrates the ability of a glue to bind corneal surfaces has been published in the June edition of the journal Investigative Ophthalmology ...
Merging tissue and electronics
2012-08-27
CAMBRIDGE, MA -- To control the three-dimensional shape of engineered tissue, researchers grow cells on tiny, sponge-like scaffolds. These devices can be implanted into patients or used in the lab to study tissue responses to potential drugs.
A team of researchers from MIT, Harvard University and Boston Children's Hospital has now added a new element to tissue scaffolds — electronic sensors. These sensors, made of silicon nanowires, could be used to monitor electrical activity in the tissue surrounding the scaffold, control drug release or screen drug candidates for their ...
The IABP-SHOCK II study
2012-08-27
Munich, Germany – A balloon pump inserted in the aorta is currently the most widely used support device in the treatment of cardiogenic shock and, since its introduction in 1968, has been used in several million people. However, there is still only limited evidence that the intraaortic balloon pump (IABP), one of the oldest medical devices in cardiology, is actually beneficial for the patient. Only a few registry studies and clinical trials have shown that the IABP can improve blood pressure and the perfusion of the coronary arteries.
Based on these studies, international ...
MBL scientists discover nerves control iridescence in squid’s remarkable 'electric skin'
2012-08-27
MBL, WOODS HOLE, MA-- Squid's colorful, changeable skin enables the animal--and their close relatives, cuttlefish and octopus--to display extraordinary camouflage, the speed and diversity of which is unmatched in the animal kingdom.
But how squid control their skin's iridescence, or light-reflecting property, which is responsible for the animal's sparkly rainbow of color, has been unknown.
In a new study, MBL (Marine Biological Laboratory) researchers Paloma Gonzalez Bellido and Trevor Wardill and their colleagues report that nerves in squid skin control the animal's ...
The PROTECT study
2012-08-27
Munich, Germany – Rates of stent thrombosis at three years were low and comparable between zotarolimus-eluting and sirolimus-eluting stents, according to findings from the PROTECT study described here today at ESC Congress 2012.
Presenting the results, Professor William Wijns from the Cardiovascular Center in Aalst, Belgium, said that the decline in rates of stent thrombosis seen recently and in the PROTECT (Patient Related OuTcomes with Endeavor versus Cypher Stenting) study was probably explained by several factors, including "improvements in patient selection, procedural ...
The FAST-MI program study
2012-08-27
Munich, Germany – Data from four French nationwide registries of STEMI (ST-elevation myocardial infarction) patients initiated five years apart and covering more than 15 years show that mortality rate decreased by 68% over this period, from 13.7% to 4.4%. Around one quarter of this mortality reduction could be attributed to a change in patient characteristics.
Even after adjusting for the use of primary percutaneous coronary intervention (PCI) and reperfusion therapy, there still remained a substantial decrease in early mortality rate (>60%), underlining the importance ...
The ASTRID study
2012-08-27
Munich, Germany – The German Aortic Valve Registry (GARY) was started in July 2010 and is the only registry so far to include both transcatheter aortic valve implantation (TAVI) and conventional aortic valve replacements and repair.(1) The intention is to deliver a complete picture of current and future practice of treating aortic valve disease and to deliver reliable data on the short and long-term outcome of different treatment strategies. This specifically includes data about quality of life before and after treatment besides numerous medical variables.
Participation ...
The ACCESS-EU study
2012-08-27
Munich, Germany –The percutaneous catheter-based treatment of mitral regurgitation with the MitraClip system improves symptoms and cardiac function at one-year, according to results of a prospective observational study presented here today at ESC Congress 2012.
ACCESS-EUROPE (ACCESS-EU) was a multicentre study of the MitraClip system in a commercial setting in 567 patients enrolled at 14 European sites, the largest group of patients evaluated to date. The results were presented by the study's co-principal investigator Professor Wolfgang Schillinger of the Universitätsmedizin ...
The ORIGIN-GRACE study
2012-08-27
Munich, Germany – A sub-study of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial, designed to investigate the effect of insulin glargine and omega-3 fatty acids on atherosclerosis progression, has found that, compared to standard care, only insulin glargine (a long-acting insulin) had a "modest" statistically non-significant reducing effect on the primary outcome of rate of change in maximum carotid intima media thickness (CIMT) at 12 carotid sites.
However, while insulin glargine did significantly reduce the secondary outcomes of the study ...
pH-sensitive liposomal cisplatin improves peritoneal carcinomatosis treatment without side-effects
2012-08-27
Scientists at the Oswaldo Cruz Foundation and Federal University of Minas Gerais, led by Dr. Andréa Teixeira-Carvalho and Dr. Mônica Cristina de Oliveira, have developed and characterized a circulating and pH-sensitive liposome containing cisplatin (SpHL-CDDP) aiming to promote the release of cisplatin near the tumor as well as decreasing toxicity. The development of analog drugs and new formulations are current strategies for increasing the effectiveness and safety of cisplatin as an anti-peritoneal carcinomatosis drug. The results, which appear in the August 2012 issue ...